{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:52:31Z","timestamp":1791229951929,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T00:00:00Z","timestamp":1487548800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00467-017-3612-9","type":"journal-article","created":{"date-parts":[[2017,2,20]],"date-time":"2017-02-20T02:47:21Z","timestamp":1487558841000},"page":"1081-1087","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Successful discontinuation of eculizumab under immunosuppressive therapy in DEAP-HUS"],"prefix":"10.1007","volume":"32","author":[{"given":"Agnes","family":"Hackl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus","family":"Ehren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kirschfink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Zipfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodo B.","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz T.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6511-5023","authenticated-orcid":false,"given":"Sandra","family":"Habbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,20]]},"reference":[{"key":"3612_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","volume":"31","author":"C Loirat","year":"2016","unstructured":"Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Fr\u00e9meaux-Bacchi V, HUS International (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15\u201339","journal-title":"Pediatr Nephrol"},{"key":"3612_CR2","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00467-010-1555-5","volume":"25","author":"D Kavanagh","year":"2010","unstructured":"Kavanagh D, Goodship T (2010) Genetics and complement in atypical HUS. Pediatr Nephrol 25:2431\u20132442","journal-title":"Pediatr Nephrol"},{"key":"3612_CR3","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00467-010-1446-9","volume":"25","author":"PF Zipfel","year":"2010","unstructured":"Zipfel PF, Mache C, M\u00fcller D, Licht C, Wigger M, Skerka C, European DEAP-HUS Study Group (2010) DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr Nephrol 25:2009\u20132019","journal-title":"Pediatr Nephrol"},{"key":"3612_CR4","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","volume":"111","author":"M J\u00f3zsi","year":"2008","unstructured":"J\u00f3zsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C (2008) Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency. Blood 111:1512\u20131514","journal-title":"Blood"},{"key":"3612_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.10.005","author":"TH Goodship","year":"2016","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fr\u00e9meaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodr\u00edguez de C\u00f3rdoba S, Roumenina LT, Sethi S, Smith RJ, Participants C (2016) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference. Kidney Int. doi:\n10.1016\/j.kint.2016.10.005","journal-title":"Kidney Int"},{"key":"3612_CR6","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, N\u00fcrnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169\u20132181","journal-title":"N Engl J Med"},{"key":"3612_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"LA Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar NC, Vande Walle J, Ogawa M, Bedrosian CL, Licht C (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701\u2013711","journal-title":"Kidney Int"},{"key":"3612_CR8","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/ki.2013.373","volume":"85","author":"A Sinha","year":"2014","unstructured":"Sinha A, Gulati A, Saini S, Blanc C, Gupta A, Gurjar BS, Saini H, Kotresh ST, Ali U, Bhatia D, Ohri A, Kumar M, Agarwal I, Gulati S, Anand K, Vijayakumar M, Sinha R, Sethi S, Salmona M, George A, Bal V, Singh G, Dinda AK, Hari P, Rath S, Dragon-Durey MA, Bagga A, Indian HUS Registry (2014) Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int 85:1151\u20131160","journal-title":"Kidney Int"},{"key":"3612_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00467-014-2948-7","volume":"30","author":"P Khandelwal","year":"2015","unstructured":"Khandelwal P, Gupta A, Sinha A, Saini S, Hari P, Dragon Durey MA, Bagga A (2015) Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome. Pediatr Nephrol 30:451\u2013457","journal-title":"Pediatr Nephrol"},{"key":"3612_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00467-013-2654-x","volume":"29","author":"D Noone","year":"2014","unstructured":"Noone D, Waters A, Pluthero FG, Geary DF, Kirschfink M, Zipfel PF, Licht C (2014) Successful treatment of DEAP-HUS with eculizumab. Pediatr Nephrol 29:841\u2013851","journal-title":"Pediatr Nephrol"},{"key":"3612_CR11","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","volume":"64","author":"G Ardissino","year":"2014","unstructured":"Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M (2014) Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis 64:633\u2013637","journal-title":"Am J Kidney Dis"},{"key":"3612_CR12","doi-asserted-by":"publisher","first-page":"e1764","DOI":"10.1542\/peds.2013-1594","volume":"133","author":"B Diamante Chiodini","year":"2014","unstructured":"Diamante Chiodini B, Davin JC, Corazza F, Khaldi K, Dahan K, Ismaili K, Adams B (2014) Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome. Pediatrics 133:e1764\u2013e1768","journal-title":"Pediatrics"},{"key":"3612_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/ped.12469","volume":"57","author":"M Hisano","year":"2015","unstructured":"Hisano M, Ashida A, Nakano E, Suehiro M, Yoshida Y, Matsumoto M, Miyata T, Fujimura Y, Hattori M (2015) Autoimmune-type atypical hemolytic uremic syndrome treated with eculizumab as first-line therapy. Pediatr Int 57:313\u2013317","journal-title":"Pediatr Int"},{"key":"3612_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","volume":"66","author":"G Ardissino","year":"2015","unstructured":"Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V (2015) Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis 66:172\u2013173","journal-title":"Am J Kidney Dis"},{"key":"3612_CR15","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1053\/j.ajkd.2013.07.011","volume":"63","author":"F Fakhouri","year":"2014","unstructured":"Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Ch\u00e2telet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Fr\u00e9meaux-Bacchi V (2014) Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. Am J Kidney Dis 63:40\u201348","journal-title":"Am J Kidney Dis"},{"key":"3612_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.06440616","volume":"12","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Fila M, Prov\u00f4t F, Delmas Y, Barbet C, Ch\u00e2telet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Fr\u00e9meaux-Bacchi V (2017) Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol 12:50\u201359","journal-title":"Clin J Am Soc Nephrol"},{"key":"3612_CR17","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1007\/s00467-014-2817-4","volume":"29","author":"S Johnson","year":"2014","unstructured":"Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, Karpman D, Landau D, Langman C, Licht C, Pecoraro C, Riedl M, Siomou E, van de Kar N, Walle JV, Loirat C, Taylor CM (2014) An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 29:1967\u20131978","journal-title":"Pediatr Nephrol"},{"key":"3612_CR18","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.3109\/0886022X.2014.917574","volume":"36","author":"H Green","year":"2014","unstructured":"Green H, Harari E, Davidovits M, Blickstein D, Grossman A, Gafter U, Gafter-Gvili A (2014) Atypical HUS due to factor H antibodies in an adult patient successfully treated with eculizumab. Ren Fail 36:1119\u20131121","journal-title":"Ren Fail"},{"key":"3612_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2215\/CJN.01260212","volume":"8","author":"J Hofer","year":"2013","unstructured":"Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, W\u00fcrzner R, Jungraithmayr T, German-Austrian HUS Study Group (2013) Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 8:407\u2013415","journal-title":"Clin J Am Soc Nephrol"},{"key":"3612_CR20","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2010030315","volume":"21","author":"MA Dragon-Durey","year":"2010","unstructured":"Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, Andr\u00e9 JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Fr\u00e9meaux-Bacchi V (2010) Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21:2180\u20132187","journal-title":"J Am Soc Nephrol"},{"key":"3612_CR21","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00467-014-2767-x","volume":"29","author":"C Licht","year":"2014","unstructured":"Licht C, Noone D (2014) Treatment of DEAP-HUS\u2014seeking the best strategy. Pediatr Nephrol 29:941\u2013942","journal-title":"Pediatr Nephrol"},{"key":"3612_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.imbio.2013.06.004","volume":"219","author":"R Watson","year":"2014","unstructured":"Watson R, Lindner S, Bordereau P, Hunze EM, Tak F, Ngo S, Zipfel PF, Skerka C, Dragon-Durey MA, Marchbank KJ (2014) Standardisation of the factor H autoantibody assay. Immunobiology 219:9\u201316","journal-title":"Immunobiology"},{"key":"3612_CR23","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00467-014-2813-8","volume":"30","author":"LT Weber","year":"2015","unstructured":"Weber LT (2015) Therapeutic drug monitoring in pediatric renal transplantation. Pediatr Nephrol 30:253\u2013265","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-017-3612-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-017-3612-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-017-3612-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T12:10:12Z","timestamp":1492690212000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-017-3612-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,20]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["3612"],"URL":"https:\/\/doi.org\/10.1007\/s00467-017-3612-9","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,20]]}}}